A5039625310- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes and associated disorders
- Diabetic Foot Ulcer Assessment and Management
- Pituitary Gland Disorders and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Diabetes Management and Education
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- Sepsis Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Metabolism, Diabetes, and Cancer
- Cancer Research and Treatments
- Myasthenia Gravis and Thymoma
- Cerebral Palsy and Movement Disorders
- Adipokines, Inflammation, and Metabolic Diseases
- COVID-19 Clinical Research Studies
- Cardiac, Anesthesia and Surgical Outcomes
St Vincent's Hospital
2019-2025
St Vincents Institute of Medical Research
2019-2023
The University of Melbourne
2018-2023
Peter MacCallum Cancer Centre
2020
The Royal Melbourne Hospital
2018-2020
Royal Hobart Hospital
2016
OBJECTIVE To investigate if early electronic identification and bedside management of inpatients with diabetes improves glycemic control in noncritical care. RESEARCH DESIGN AND METHODS We investigated a proactive or intervention model care (whereby an inpatient team electronically identified individuals aimed to provide within 24 h admission) compared usual (a referral-based consultation service). conducted cluster randomized trial on eight wards, consisting 10-week baseline period (all...
Background Despite improved response to combined ipilimumab and nivolumab (hereafter, IpiNivo) treatment for advanced melanoma, many patients exhibit primary or acquired resistance. This, with high risk of immune-related adverse events, makes identifying markers predictive outcomes desirable. Purpose To investigate the prognostic value fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT parameters at baseline as part monitoring in melanoma undergoing IpiNivo treatment. Materials Methods This...
Abstract Background In recent years, immune checkpoint blockade has become a standard therapy for wide range of cancers. Adverse events, including endocrinopathies, result from the induction autoimmunity. Case report We case series nine individuals who presented with immunotherapy‐induced Type 1 diabetes between 2015 and 2017. Onset occurred within 12 weeks commencing therapy. Anti‐glutamic acid decarboxylase antibodies were present in six people. Retrospective testing islet pre‐treatment...
Background: FDG-PET/CT used for immune checkpoint inhibitor (ICI) response assessment can incidentally identify immune-related adverse events (irAEs), including thyroiditis. This study aimed to correlate the time course of evidence thyroiditis with clinical and biochemical evolution thyroid dysfunction. Methods: A retrospective review was performed by two independent blinded nuclear medicine physicians (NMPs) thyroidal FDG uptake in 127 patients who underwent PET/CT between January 2016 2019...
Introduction Hypophysitis is reported in 8.5%–14% of patients receiving combination immune checkpoint inhibition (cICI) but can be a diagnostic challenge. This study aimed to assess the role routine imaging performed during therapeutic monitoring anti-CTLA-4/anti-PD-1 treatment identification hypophysitis and relationship findings clinical criteria. Methods retrospective cohort identified treated with cICI between January 2016 2019 at quaternary melanoma service. Medical records were...
Abstract Background High Risk Foot Clinic (HRFC) patients have foot ulceration commonly associated with poorer quality of life (QoL). A positive SARC‐F test is predictive sarcopenia. The objective this study to investigate whether status lower QoL among attendees HRFC, which currently unknown. Methods and results In cross‐sectional ambulatory HRFC were recruited at metropolitan tertiary referral hospital over one year. Demographics, comorbidities, EQ‐5D‐3L (EuroQol Group) outcomes collected....
Abstract Aim To determine the clinical and biochemical variables associated with change in HbA1c patients type 2 diabetes who start sodium‐glucose linked transporter (SGLT) inhibitor therapy. Methods We performed a prospective cohort study (ACTRN12616000833460) of 48 adults (30 male, 18 female) attended tertiary hospital clinic. Fasting serum urine samples, collected during clinic visits prior to at 1, 12 24 weeks after commencing SGLT treatment, were analysed for HbA1c, electrolytes, urea,...
Abstract Background: Hypophysitis is one of the commonly reported adverse events related to immune checkpoint inhibitors (ICI), and incidence expected rise with increased use combined programmed cell death protein 1 (PD1) cytotoxic T lymphocyte associated 4 (CTLA4) blockade. The clinical diagnosis can be delayed due non-specific symptoms. At our centre, subjects undergo periodic imaging assess tumour response ICI. We reviewed whether neuroimaging studies guide us in hypophysitis early...
Abstract Background: Immune checkpoint blockade is now established as standard of care in several malignancies. Trials involving combined cytotoxic T lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 (PD1) demonstrate improved tumour responses melanoma but at the cost severe grade 3-4 immune related adverse events (irAEs) 55%, endocrine irAEs up to 10% [1]. Immune-mediated damage glands can be a diagnostic management challenge. We aimed review incidence, biochemical...
A relationship between diabetes, glucose and COVID-19 outcomes has been reported in international cohorts. This study aimed to assess the hyperglycaemia patient those hospitalised with during first year of Victorian pandemic prior novel variants vaccinations.
We previously showed that a proactive inpatient diabetes service decreased adverse glycemia (AG) and hospital acquired infections (RAPIDS: ADA2017, 231-OR). To further focus our care on high-risk inpatients, we investigated clinical risk factors associated with AG. analyzed multiple variables in 643 consecutive inpatients or new hyperglycemia (random BG ≥11.1mmol/L). Capillary from day 2 of admission until discharge (censored at 14) were analyzed. AG was defined as <4 >15mmol/L...
Background: A model of proactive diabetes care was investigated to improve glycaemic control in hospital.
10041 Background: Predictors of outcomes immune checkpoint inhibitors (ICI) are desirable. We aim to investigate the prognostic value 18 F-fluorodeoxyglucose-PET/CT (FDG-PET) parameters at baseline and response monitoring patients (pts) with advanced melanoma receiving ipi/nivo. Methods: From 2016-2019, pts who received ipi/nivo had PET Response Criteria In Solid Tumors (PERCIST) measurable lesions on FDG-PET were included. Baseline whole-body metabolic tumor volume (wbMTV), stage,...